DaVita/$DVA

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About DaVita

DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.

Ticker

$DVA

Primary listing

NYSE

Industry

Health Care Providers & Services

Employees

76,000

ISIN

US23918K1088

DaVita Metrics

BasicAdvanced
$11B
13.94
$10.11
1.14
-

What the Analysts think about DaVita

Analyst ratings (Buy, Hold, Sell) for DaVita stock.

Bulls say / Bears say

DaVita raised its 2024 profit forecast, anticipating adjusted per-share earnings between $9.25 and $10.05, up from the previous range of $9.00 to $9.80, driven by strong demand for kidney dialysis services. (reuters.com)
In Q4 2024, DaVita reported a 4.7% increase in sales to $3.29 billion, surpassing Wall Street expectations and indicating robust operational performance. (newsminimalist.com)
DaVita's expansion into international markets, including Brazil, Colombia, Chile, and Ecuador, through acquisitions from Fresenius Medical Care, aligns with its strategic growth initiatives. (markets.businessinsider.com)
DaVita's 2025 profit forecast of $10.20 to $11.30 per share fell below analysts' expectations, leading to an 11% drop in after-hours trading, attributed to rising patient care costs. (reuters.com)
The effectiveness of Novo Nordisk's Ozempic in slowing kidney disease progression poses a potential threat to DaVita's dialysis services demand, causing a significant stock decline. (investing.com)
DaVita's high debt-to-equity ratio of 23.18 raises concerns about financial leverage and potential risks associated with servicing its substantial debt load. (marketbeat.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.

DaVita Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

DaVita Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $DVA

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs